These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 33973371)

  • 1. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
    Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS).
    Bastard L; Claudepierre P; Penso L; Sbidian E; Pina Vegas L
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38485454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
    Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
    JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
    Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
    Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
    Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion.
    Schneeweiss MC; Savage TJ; Wyss R; Jin Y; Schoder K; Merola JF; Sidbury R; Oduol T; Schneeweiss S; Glynn RJ
    JAMA Dermatol; 2023 Mar; 159(3):289-298. PubMed ID: 36753234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
    Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
    JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elderly psoriatic patients under biological therapies: an Italian experience.
    Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment persistence of biologics among patients with psoriatic arthritis.
    Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
    Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.